AGENDA AT A GLANCE

Day 1 | 3 November 2026
Day 2 | 4 November 2026
Biologics Manufacturing Strategy
AI & Data Analytics for Process Robustness
Coffee & Networking Break
Next-Gen Upstream Processing
Building Future-Ready Biomanufacturing Capacity
Lunch & Poster Exhibition
Downstream Purification Optimisation
Supply Chain Resilience and Logistics
Tea & Networking Break
Industry Roundtables
Closing Panel Discussion – Future of European Biomanufacturing
End of Conference Day 1
End of Conference
VIEW DAY 1
VIEW DAY 2

Day 1

3 November 2026

GO TO DAY 2

8:00

Registration & Welcome Coffee

8:50

IMAPAC & Chairman's Welcome Address

Dr Uwe Gottschalk, Former CSO, Lonza, France

Biologics Manufacturing Strategy

9:00

AI-Driven Biologics Manufacturing: Building Smarter, Faster & More Resilient Operations

  • Integrating AI to optimize upstream and downstream bioprocess parameters in real time
  • Using predictive analytics to reduce batch failures and improve yield consistency
  • Enabling faster tech transfer and scale-up through digital twins and simulation models
  • Strengthening supply chain resilience with AI-driven demand forecasting and risk detection
Ian Baldacchino, Vice President, Global Head of Internal Manufacturing Quality, UCB, Belgium
Mathias Van den Borre, Head of Digital Innovation, Global Quality, UCB, Belgium

9:30

Topic - TBC

Reserved for Inprocess LSP

10:00

Supply Chain - Intelligence to Increase the Volume & Velocity of Decisions (TBC)

  • Leveraging real-time data analytics to improve visibility across end-to-end biologics supply networks
  • Using AI-driven forecasting to accelerate decision-making on demand shifts, capacity, and inventory
  • Integrating cross-functional data streams to reduce bottlenecks and improve responsiveness
  • Enhancing risk detection and scenario planning to support faster, more confident supply chain decisions
Niveth Richard, Supply Chain Decision Intelligence Lead, GSK, UK

10:30

Topic- TBC

Dirk Boehm, Site Head DS Penzberg (VP), Roche, Germany

11:00

Networking Break

Next-Gen Upstream Processing: Intensification & Perfusion

11:40

Building Scalable and Robust Biologics Platforms Through Integrated Process and Formulation Development

  • Evaluating the cost-benefit of continuous vs batch manufacturing
  • Fewer operators and smaller facilities help offset high labor and real estate costs.
  • Works best with predictable demand and long production runs to maximize asset utilization.
  • Real-time monitoring reduces deviations and accelerates time-to-market, improving overall economics.
Harsha Reddy, Group Lead - Head Upstream Process Development, CMC Bioprocess Lead, Accord BioPharma, UK

12:10

Reserved for Solution Provider

12:40

Unlocking Biologics Manufacturing Potential: Case Studies in Data Science Applications

  • Applying data science to optimize upstream and downstream process performance and reduce variability
  • Using advanced analytics to identify root causes of batch deviations and improve yield consistency
  • Leveraging predictive models to enhance process control, scale-up success, and tech transfer efficiency
  • Demonstrating real-world case studies where data-driven insights improved cost, quality, and time-to-market
Shyam Panjwani, Principal Biotech Data Scientist, CMC Statistician, Bayer, USA

13:10

Lunch & Poster Presentation

Downstream Purification Optimisation

14:10

AI-Enabled Downstream Purification Optimisation: Improving Yield, Purity & Process Robustness

  • Optimising chromatography and filtration steps using data-driven process modelling and real-time monitoring
  • Reducing product loss and impurity breakthrough through improved control of critical process parameters
  • Integrating PAT and advanced analytics to enable faster troubleshooting and cycle time reduction
  • Enhancing scalability and robustness of purification processes from lab to commercial manufacturing
Gavin Wild, Head of Early Process Sciences, UCB

14:40

Achieving Substantial Cost Savings through Downstream Process Optimisation

  • Reducing buffer consumption, resin usage, and cycle times through intensified and optimised purification strategies
  • Improving yield recovery and product consistency to minimise batch losses and reprocessing costs
  • Implementing advanced analytics and PAT tools to enable real-time control and efficiency gains
  • Streamlining downstream workflows to lower overall COGS while maintaining quality and regulatory compliance

15:00

Optimising Downstream Purification for Higher Yield, Consistency and Commercial Scalability

  • Improving recovery and purity across increasingly complex biologics
  • Balancing process robustness, cost, and speed during scale-up
  • Using process data to identify bottlenecks and reduce variability
  • Building purification platforms that support reliable commercial supply

15:30

Networking Break

16:00

Interactive Roundtable Sessions:

  • From Pilot to Scale: What Does Successful AI Adoption Really Look Like in Pharma? (TBC)
Ian Baldacchino, Vice President, Global Head of Internal Manufacturing Quality, UCB, Belgium
Mathias Van den Borre, Head of Digital Innovation, Global Quality, UCB, Belgium
  • Is Your Data Ready for AI? Building the Foundations for Scalable ML (TBC)
Niveth Richard, Supply Chain Decision Intelligence Lead, GSK, UK
  • Scaling Biologics Manufacturing for Future Demand (TBC)
Dirk Boehm, Site Head DS Penzberg (VP), Roche, Germany
  • Maximising Drug Product Manufacturing
Alexander Hempel, Manager Drug Substance Manufacturing, Avethera, Germany

17:00

Cocktail Reception

18:00

END OF DAY 1

Want to Speak at This Event?

Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.

Apply to Speak

Day 2

4 November 2026

GO TO DAY 1

8:50

IMAPAC & Chairman's Welcome Address

AI & Data Analytics for Process Robustness

9:00

Opening Keynote: Data-Driven Biopharma: Integrating Real-World Evidence into Development and Lifecycle Strategy

  • Leveraging real-world evidence (RWE) to complement clinical trial data and strengthen regulatory and payer submissions
  • Integrating diverse data sources to identify patient subgroups, treatment outcomes, and unmet medical needs
  • Using advanced analytics to support lifecycle management, label expansion, and post-market surveillance
  • Enabling faster, more informed decision-making across development, commercialization, and market access strategies
Aliki Taylor, Executive Director, RWE TA Head Oncology, Gilead Sciences, UK

9:30

Reserved for Solution Provider

10:00

Single-Cell RNA Sequencing (scRNA-seq) Workflow: From Sample to Insight

  • Isolating and capturing individual cells using microfluidics or droplet-based platforms for high-resolution profiling
  • Performing reverse transcription and library preparation to generate single-cell gene expression datasets
  • Sequencing and processing data through bioinformatics pipelines for quality control and alignment
  • Clustering and interpreting cellular heterogeneity to identify subpopulations and functional states
Dr Aurelien Bunga, Senior Scientist, Rinri Therapeutics, UK

10:30

Networking Break

11:10

Predicting the Future: Kinetic Modelling for Smarter Stability Decisions Across the Pharmaceutical Lifecycle

  • De-risking early clinical development through accelerated stability prediction with quantified uncertainty
  • Optimising cold chain design and setting evidence-based temperature excursion limits
  • Accelerating shelf life determination and supporting regulatory submissions with GMP-ready outputs
  • Enabling real-time stability comparability assessment across batches, sites and manufacturing changes
Dr.Warren Roche, Biostatician Lead, Argenx, Belgium

Building Future-Ready Biomanufacturing Capacity

11:40

Optimising Strategic Network Design through Make vs Buy Decision Frameworks

  • Evaluating internal vs outsourced manufacturing capabilities
  • Designing flexible and scalable manufacturing networks
  • Balancing cost, control, and speed to market
  • Managing risks across global production and supply networks
Dr John Bridgeman, Chief Scientific Officer, Immunokey, UK

12:10

Vaccine Manufacturing Networks in Low- and Middle-Income Countries

  • Strengthening regional vaccine manufacturing capacity and supply resilience in LMICs
  • Building sustainable technology transfer and local manufacturing partnerships
  • Overcoming infrastructure, workforce, and regulatory challenges across emerging markets
  • Enhancing equitable access through scalable and future-ready vaccine manufacturing networks
Vishal Mukund Sonje, Senior Vaccine Manufacturing Lead, CEPI, UK

13:00

Lunch & Poster Presentation

Supply Chain Resilience and Logistics

14:00

Building Anti-Fragile Supply Chains: AI, Predictive Analytics, and Geographic Diversification

  • Leveraging predictive analytics to anticipate and mitigate disruptions
  • Diversifying supply chains to reduce geographic risk
  • Enhancing visibility and responsiveness through digital tools
  • Building resilient and adaptive supply chain strategies
Valerie Chambard-Benalleg, Manufacturing Supply Chain Lead, CEPI, UK

14:30

Typical watchouts to best design commercial supply chain before launches for small biotechs

  • Identifying common pitfalls in early supply chain planning
  • Aligning production capacity with launch forecasts and demand
  • Managing limited resources while ensuring scalability
  • Preparing for regulatory and distribution challenges
Mrunal Panwala, Sr. Manager, Site Planning - Supply Chain, Moderna, UK

15:00

Designing resilient supply chains for linkers and payloads

  • Addressing sourcing and availability challenges for critical components
  • Managing quality and regulatory requirements for specialised materials
  • Building redundancy and supplier diversification strategies
  • Ensuring secure and scalable supply for ADC production

15:30

Networking Break

Closing Panel Discussion

16:00

CLOSING PANEL

Future of European Biomanufacturing

  • Europe’s biomanufacturing future depends on scaling advanced facilities while maintaining high regulatory and quality standards.
  • Strategic investment in automation, digitalisation, and AI will be critical to offset high operating costs.
  • Strengthening local supply chains will improve resilience and reduce dependency on external geographies.
  • Collaboration across academia, industry, and CDMOs will accelerate innovation and capacity expansion.
Maurice Murphy, Executive Director Plant Manager, Amgen, Ireland
Julia Hinteramskogler, Head of Technical Development, Elaris, Austria

16:45

Chairman's Closing Remarks

17:00

END OF DAY 2

Get Your Ticket